Denali Therapeutics (DNLI) Operating Expenses (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Operating Expenses of $137.4 million for Q1 2026, down 5.65% year-over-year from $145.6 million in Q1 2025, and little changed quarter-over-quarter from $137.4 million in Q4 2025.
Denali Therapeutics (DNLI) Operating Expenses (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Operating Expenses for 10 consecutive years, with $137.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 5.65% year-over-year to $137.4 million; the TTM figure through Mar 2026 stood at $547.1 million (up 6.19% YoY), while the FY2025 annual figure was $555.3 million, up 10.65% from the prior year.
- Operating Expenses steadied at $137.4 million in Q1 2026 per DNLI's latest filing, from $137.4 million in the prior quarter.
- Across five years, Operating Expenses topped out at $156.0 million in Q1 2023 and bottomed at $108.6 million in Q1 2022.
- Historically, Operating Expenses has averaged $127.7 million across 5 years, with a median of $129.8 million in 2024.
- Annual changes were most pronounced in 2023 — Operating Expenses surged 43.55% — and 2024, when it decreased 15.2%.
- Denali Therapeutics' Operating Expenses stood at $115.6 million in 2022, then climbed by 14.65% to $132.6 million in 2023, then retreated by 2.06% to $129.8 million in 2024, then climbed by 5.79% to $137.4 million in 2025, then declined by 0.01% to $137.4 million in 2026.
- Business Quant data shows DNLI's Operating Expenses at $137.4 million in Q1 2026, $137.4 million in Q4 2025, and $137.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 134.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 134.15 Mn |
| Mar 31, 2026 | 137.36 Mn |
| Dec 31, 2025 | 137.37 Mn |
| Sep 30, 2025 | 137.43 Mn |
| Jun 30, 2025 | 134.96 Mn |
| Mar 31, 2025 | 145.58 Mn |
| Dec 31, 2024 | 129.85 Mn |
| Sep 30, 2024 | 123.19 Mn |
| Jun 30, 2024 | 116.59 Mn |
| Mar 31, 2024 | 132.25 Mn |
| Dec 31, 2023 | 132.57 Mn |
| Sep 30, 2023 | 115.06 Mn |
| Jun 30, 2023 | 123.64 Mn |
| Mar 31, 2023 | 155.96 Mn |
| Dec 31, 2022 | 115.63 Mn |
| Sep 30, 2022 | 111.05 Mn |
| Jun 30, 2022 | 113.90 Mn |
| Mar 31, 2022 | 108.64 Mn |
| Dec 31, 2021 | 89.64 Mn |
| Sep 30, 2021 | 90.88 Mn |